Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis

Cystic Fibrosis Clinical Trial

— MUCOLAX  

Official title:

EFFECT OF POLYETHYLENE GLYCOL TREATMENT ON INTESTINAL INFLAMMATION ASSOCIATED WITH CYSTIC FIBROSIS IN CHILDREN

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04458129
• Other study ID #: CHUBX 2019/25
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 8, 2020
• Est. completion date: July 8, 2022

Study information

• Verified date: June 2020
• Source: University Hospital, Bordeaux
• Contact: Raphaël R ENAUD, MD
• Phone: 0556799824
• Email: raphael.enaud[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the study is to evaluate the effectiveness of polyethylene glycol treatment on intestinal inflammation in children with cystic fibrosis. In this test, a method adapted from the Fleming one-step scheme will be used. The success rate is measured by the proportion of patients with fecal calprotectin levels < 250 µg/g at 3 months after treatment initiation.

Description:

Cystic fibrosis is one of the most frequent serious genetic diseases in France (7000 patients). It is the consequence of mutations in the CFTR gene, encoding a protein involved in the hydro-electrolytic balance of secretions. Beyond the well-known lung damage in these patients, intestinal inflammation is present in the majority of patients.

While advances in the management of cystic fibrosis are increasing patient life expectancy, other issues are emerging, including the impact of this chronic intestinal inflammation on the nutritional status and high risk of digestive cancers (Maisonneuve, 2013; Garg and Ooi, 2017; Yamada, 2018).

Currently, no management is proposed to treat this intestinal inflammation. The use of laxatives to fluidize digestive secretions and restore a digestive ecosystem close to the healthy subject could constitute a new therapeutic approach to this intestinal inflammation, as previously shown in the mouse model of cystic fibrosis (De Lisle, 2007). However, to date, to the investigator's knowledge, no studies have evaluated the effect of laxative treatment on intestinal inflammation of cystic fibrosis in humans.

This study is a bi-centric, non-comparative, prospective study for a phase II trial according to a Fleming scheme.

Study participants will take a 3-month laxative treatment with polyethylene glycol for 3 months. In addition to the inclusion visit, a follow-up visit will take place at 3 months and 3 intermediate telephone calls will be made to ensure efficacy, tolerance and compliance.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 23
• Est. completion date: July 8, 2022
• Est. primary completion date: April 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 17 Years

Eligibility

Inclusion Criteria:

• Age = 4 years old and <18 years old ;

• Patient with cystic fibrosis (sweat test > 60 mmol/l and/or molecular biology identifying mutations in the CFTR gene) with associated pancreatic insufficiency (fecal elastase <100 µg/g);

• With a rapid calprotectin assay result via the IBDoc test (Bühlmann®) superior or equal to 250 µg/g;

• Person affiliated or benefiting from a social security scheme;

• Free, informed and written consent signed by the holders of parental authority and the investigator before any examination required by the research and oral and/or written consent by the participant (depending on his/her age).

Exclusion Criteria:

• Ongoing processing that can modulate the functionality of the CFTR (such as lumacaftor-ivacaftor protein therapy);

• Patient already on polyethylene glycol or other laxative within 3 months before the inclusion visit;

• Patient with diarrhea at inclusion (diarrhea will be defined as the presence of 3 or more stools / day in the 7 days prior to the inclusion visit);

• Acute viral or bacterial diarrhea in the month prior to the inclusion visit (associated with fever);

• Cure of oral or intravenous antibiotics or antifungals in the month preceding the collection of samples;

• Change in background treatment in the month prior to the inclusion visit (oral or inhaled corticosteroid therapy, azithromycin, inhaled antibiotic therapy, inhaled antifungal agent, proton pump inhibitors);

• Taking probiotics in the month before the inclusion visit;

• Transplanted patient (on immunosuppressants);

• Patient with IBD or celiac disease;

• Patient with digestive perforation or risk of digestive perforation;

• Patient with ileus or suspicion of intestinal obstruction, symptomatic stenosis;

• History of hypersensitivity to macrogol or any of the excipients

• Holders of parental authority enjoying judicial protection.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis
• Inflammation

Intervention

Drug:
• Treatment with polyethylene glycol (Macrogol 4000)
3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Impact of a 3-month polyethylene glycol treatment on intestinal inflammation assessed by measurement of fecal calprotectin (µg / g) by an ELISA biological test	proportion of patients with fecal calprotectin <250 µg / g measured by an ELISA test 3 months after initiation of treatment with polyethylene glycol, testifying to the absence of intestinal inflammation or slight inflammation.	3 months after the inclusion visit i.e. 3 months after the initiation of treatment with polyethylene glycol
Secondary	Evolution of the digestive inflammatory response, assessed by measurement of fecal calprotectin (µg / g)	Evolution of the digestive inflammatory response, assessed by measurement of fecal calprotectin (µg / g) by an ELISA biological test between the initiation of treatment (D0) and 3 months of treatment with polyethylene glycol (M3)	Change from Baseline fecal calprotectin measurement at 3 months
Secondary	Evolution of the digestive inflammatory response, assessed by Analysis of the expression of genes involved in the inflammatory and pro-oncogenic response	Analysis of the expression of genes involved in the inflammatory and pro-oncogenic response, using NanoString Technology and the nCounters® PanCancer Immune Profiling Panel	Change from Baseline measurement at 3 months
Secondary	Evolution of the digestive symptoms, assessed by the JenAbdomen CF-score	The JenAbdomen CF-score has been described in the following publication Tabori H. et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PloS One 12,e0174463 (2017).; the JenAbdomen CF-Score is based on a CF patient-reported outcome measure (PROM) that includes all relevant gastrointestinal symptoms and their impact on subjective quality of life	Change from Baseline measurement at 3 months
Secondary	Evolution of the quality of life scores, assessed by the CFQ-R questionnaire	The CFQ-R questionnaire has been described in the following publication: Modi, A. C. & Quittner, A. L. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J. Pediatr. Psychol. 28, 535-545 (2003).; The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a disease-specific health-related quality of life (HRQOL) measure for children, adolescents and adults with cystic fibrosis (CF). It is a profile measure of HRQOL with several different domains. It has undergone extensive reliability and validity testing.; The Cystic Fibrosis Questionnaire-Revised (CFQ-R) application calculates the score derived from the CFQ-R, on a 0-100 scale with higher scores indicating better HRQoL.	Change from Baseline measurement at 3 months
Secondary	Evolution of the composition of the bacterial intestinal microbiota	The composition of the bacterial intestinal microbiota will be assessed by High-throughput sequencing and phylogenetic allocation of the bacterial flora (on MiSeq, from Illumina®)	Change from Baseline measurement at 3 months
Secondary	Evolution of the composition of the fungal intestinal microbiota	The composition of the fungal intestinal microbiota will be assessed by high-throughput sequencing and phylogenetic allocation of the fungal flora (on MiSeq, from Illumina®)	Change from Baseline measurement at 3 months
Secondary	Evolution of the pulmonary inflammation, assessed by the dosage of calprotectin in the sputum	Evolution of the Pulmonary inflammation will be assessed by measurement of salivary calprotectin (µg / g) by an ELISA biological test between the initiation of treatment (D0) and 3 months of treatment with polyethylene glycol (M3)	Change from Baseline measurement at 3 months